Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1-year survival rate of 44% ...

A Revolution Medicines drug for pancreatic cancer is showing promising signs of a possible breakthrough, after a clinical ...

Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1-year survival rate of 44% in the elraglusib ...

Improvement in median overall survival of 2.9 months and decrease in risk for death reported with elraglusib/GnP vs GnP alone.

For patients with metastatic pancreatic cancer, new treatment options are urgently needed to increase survival time and ...

Elraglusib plus chemotherapy doubled one-year survival in metastatic pancreatic cancer, showing improved outcomes in a phase ...

First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients ...

The Pancreatic Cancer Action Network (PanCAN), the leading organization dedicated to advancing progress against pancreatic ...

For more than two decades, oncologists treating advanced pancreatic cancer have watched new drugs fail to move the survival ...

Late-breaking results from the Phase III NRG GY019 trial indicate that letrozole monotherapy (L) did not demonstrate ...

Discover more about how metformin can lower odds of oesophageal squamous cell carcinoma and underlying biological pathways.

An investigational targeted therapy doubled survival compared with standard chemotherapy for pretreated individuals with ...